Burden of Early and Advanced Breast Cancer in The Netherlands

Vondeling, G.; Rozenbaum, M.; Dvortsin, Evgeni; Postma, MJ; Zeevat, F.

doi:10.1016/j.jval.2016.09.2337

Cited by 3 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eventually, one study [11] was not included because it failed to provide figures feasibly allowing for the computation of the cost-per-DALY ratio (i.e., both absolute or standardized per 100,000 persons). As a result, seven studies were included in this review, of which five [31][32][33][34][35] were also eligible for quantitative synthesis since they provided directly retrieved cost and DALY estimates. In contrast, two studies [36,37] provided only rough estimates of the costs starting from DALYs and pre-determined parameters (per-capita GDP or value of a statistical life, VSL) and therefore were kept as a comparison term for estimate difference projections.…”

Section: Study Selectionmentioning

confidence: 99%

“…The seven studies included in this review were published between 2012 and 2021. Six of these studies [32][33][34][35][36][37] adopted a societal perspective, and only one [31] chose a healthcare system perspective. Characteristics of all studies are summarized in Tables 1 and 2.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The five studies retrieving costs and DALYs from independent sources were based on national data from four countries (Korea, Mexico, the Netherlands and Portugal). These studies basically aimed at assessing health and economic burden of cancer in the relevant country: three of them [31][32][33] were longitudinal retrospective studies based on data from different time spans (i.e., 5-20 years), one [34] was designed as a prevalence study and one [35] was based on a virtual prospective cohort. Data sources included: for direct costs, national pension institutes, health authorities and insurance corporations; for indirect costs, central statistics bureaus and national ministries; and for DALYs, databases from (and/or software based on) surveys developed by supranational institutions (i.e., World Health Organization and European Union), national institutes for statistics or cancer registries.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The meta-analytic estimate of this cost-per-DALY ratio showed that this parameter could be reasonably quantified in USD 9150 (95%CI: (5560-15,050)) 2018 USD per DALY ascribable to the disease (Figure 2a). As four of the studies [31][32][33][34] included in this quantitative synthesis were conducted in high-income countries, while one [35] was set in a country with a different economic framework (upper-middle income), the same analysis was conducted excluding the latter study, resulting in a substantially unchanged estimate (USD 10,070 USD/DALY, 95%CI: (5730-17,660), Figure S1).…”

Section: Quantitative Analysesmentioning

confidence: 99%

“…The quality and risk-of-bias assessment of studies included in this review is reported in the Supplementary Material (Table S3). One study [37] turned out to be of poor quality, four studies [31,32,34,36] were classified as fair and two studies displayed valuable methodological qualities [33,35]. Interestingly, two of the included studies [32,37] lacked precise reporting of the currency and pricing date.…”

Section: Quality Assessmentmentioning

confidence: 99%

See 4 more Smart Citations

Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis

Garlasco

Nurchis

Bordino

et al. 2022

IJERPH

View full text Add to dashboard Cite

Cancers currently represent a leading cause of morbidity and mortality, and precisely estimating their burden is crucial for evidence-based decision-making. This study aimed at understanding the average costs of cancer-related disability-adjusted life years (DALYs) and highlighting possible differences in economic estimates obtained with diverse approaches. We searched four scientific databases to identify all the primary literature simultaneously investigating cancer-related costs and DALYs. In view of the different methodologies, studies were divided into two groups: those estimating costs starting from DALYs, and those independently performing cost and DALY analyses. The latter were pooled to compute costs per disease-related DALY: meta-analytic syntheses were performed for total costs and indirect costs, and in relation to the corresponding gross domestic product (GDP) per capita. The quality of included studies was assessed through the Quality of Health Economic Studies instrument. Seven studies were selected. Total and indirect pooled costs per DALY were, respectively, USD 9150 (95% CI: 5560–15,050) and USD 3890 (95% CI: 2570–5880). Moreover, the cost per cancer-related DALY has been found to be, on average, 32% (95% CI: 24–42%) of the corresponding countries’ GDP per capita. Costs calculated a priori from DALYs may lead to results widely different from those obtained after data retrieval and model building. Further research is needed to better estimate the economic burden of cancer in terms of costs and DALYs.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Quantitative Analysesmentioning

confidence: 99%

Section: Quality Assessmentmentioning

confidence: 99%

See 3 more Smart Citations

Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis

Garlasco

Nurchis

Bordino

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

Burden of lung cancer and predicted costs of occupational exposure to hexavalent chromium in the EU – The impact of different occupational exposure limits

Chen-Xu

Jakobsen

Pires

et al. 2023

Environmental Research

View full text Add to dashboard Cite

Household treatment cost of breast cancer and cost coping strategies from a tertiary facility in Ghana

Adanu

Bansah

Adedia

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

Breast cancer is the number one cause of cancer death in women globally. According to the Global cancer registry, there were 2.3 million new cases of breast cancer diagnosed in 2020 worldwide, accounting for 25% of all cancer cases in women. The data on the cost burden of breast cancer on households is limited in Ghana, it is therefore imperative that it is estimated to ensure effective planning and provision of adequate resources for breast cancer treatment. This cost-of-illness study estimates the household treatment cost of breast cancer and the cost coping strategies used by patients. This cost-of-illness study was conducted at the surgical unit (Surgical unit 2) of the Korle Bu Teaching Hospital (KBTH), with 74 randomly selected patients and their accompanying caregiver(s). Data was collected using structured questionnaire on direct, indirect and intangible costs incurred and coping strategies used by patients and their households. The results are presented in descriptive and analytic cost statistics. Most of the patients were aged 40–69 years and were married with moderate education levels. Nearly 57% of patients earn an income of USD 370 or less per month. The average household expenditure was USD 990.40 (medical cost: USD 789.78; non-medical cost: USD 150.73; and indirect cost: USD 50). The publicly provided mechanism was the most utilized cost coping strategy. The direct, indirect and intangible costs associated with breast cancer treatment had significant financial and psychological implications on patients and their households. Moreover, poorer families are more likely to use the publicly provided strategies to cope with the increasing cost of breast cancer treatment.

show abstract

Burden of Early and Advanced Breast Cancer in The Netherlands

Cited by 3 publications

References 0 publications

Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis

Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis

Burden of lung cancer and predicted costs of occupational exposure to hexavalent chromium in the EU – The impact of different occupational exposure limits

Household treatment cost of breast cancer and cost coping strategies from a tertiary facility in Ghana

Contact Info

Product

Resources

About